[카테고리:] Uncategorized

Although the interest in cannabis is increasing,
the research on the topic continues to encounter the following essential obstacles:

• Regulatory limits to sourcing and trial approval, especially in nations which have strict control over cannabis.
• The absence of standardized formulations, which produces variable outcomes of studies.
• Scanty long-term evidence, particularly with regards to high-THC concentrates and more recent delivery methods (e.g., vaping, dabbing).

Achieving progress in the science of marijuana will necessitate policy change, crossed-discipline cooperation, and funding into longitudinal studies. With the increasing number of jurisdictions where cannabis is legalized,
the demand in high-quality, evidence-based guidance is going to increase.

Social and Economic Impacts of Marijuana Legalization

The two issues of legalizing marijuana, either medically or recreationally,
have illustrated significant social, economic, and legal consequences. These consequences go far beyond the sphere of personal health affecting the state budget, labor markets, criminal justice reform, and equity programs. As compulsoriers and interested groups consider the probable long-term impacts of legalizing cannabis,
they need a balanced appreciation of both rewards and predicaments.

Tax revenue and Economic Growth

The economic potential of legalization is one of the most referenced benefits of legalization. Legal cannabis markets are already bringing in high tax revenues, creating jobs, and enticing privately funded agriculture, biotechnology, retail, and manufacturing. For example:

• Legal cannabis sales in the United States topped $30 billion in 2024, and tax collections topped $4 billion in legal states.
• The colors of Colorado and California have used the tax on cannabis to fund public education, infrastructure, mental health, and drug prevention and education.
• Hundreds of thousands of jobs have been supported by the industry, both in growth (cultivation), distribution, quality control, regulatory compliance and retail sales.

Ancillary businesses, which include security services, software, packaging, legal consulting, and lab testing also get a chance with legalization and increase the total economic impact of cannabis.

Criminal Justice Reform and Public Safety

Legally, the marijuana legalization has led to huge criminal justice reform. The important results are:

• Decline in arrests: Legalization has significantly lowered the number of people being arrested in relation to the possession of marijuana thereby cutting down on court and police workloads. The ACLU reports that before many places legalized marijuana, marijuana-related arrests comprised more than 40 percent of all drug-related arrests.
• Saving money: By forgoning the low level marijuana crimes, the states have saved millions of money which could be diverted to deal with the serious crimes.
• Expungement and equity: However, a number of legalization initiatives will offer record clearing of past cannabis-related offenses. Social equity programs have been established by some states to assist entrepreneurs that belong to communities that have been disproportionately affected by prohibition.

But still, inequalities exist. Even after legalization, enforcement in certain jurisdictions continues to have a disproportionate impact on communities of color. Equity in licensing, access to capital and representation in the industry continues to be a challenge.

Over the last 20 years, scientific research on marijuana has grown tremendously due to increased curiosity on its therapeutic potential and its effect on population health. Nonetheless, in spite of the regulatory challenges, a virtually growing literature base currently serves to guide our perception of the pharmacology,
therapeutics, harms, and socio-behavioral consequences of cannabis. Nevertheless, there are numerous topics that are still under-researched,
and it can be explained by the federal Schedule I status of marijuana in the United States,
which restrictedaccess to it by researchers in the past.

Therapeutic Efficacy: Evidence-Based Usage

There is great evidence that cannabinoids should be used on precise medical indication. For instance:

A 2017 report by the National Academies of Sciences, Engineering,
and Medicine (NASEM) determined that cannabinoids have a role in chronic pain, mostly neuropathic pain,
and that oral cannabinoids are effective antiemetics in chemotherapy-induced nausea and vomiting.

The use of CBD in epilepsy, particularly in rare and severe childhood forms of Dravet syndrome and Lennox-Gastaut syndrome, also has high-quality evidence.

• The use of cannabis in the enhancement of spasticity and sleep disorders linked to multiple sclerosis (MS) in chronic illnesses has moderate evidence.

The rest of the potential therapeutic uses, such as cannabis to treat anxiety, PTSD, depression, or inflammatory diseases,
are mostly in the exploratory stage, with conflicting results or small clinical trials. To prove these possible applications, standardization of cannabis products,
better dosing methodologies and big randomized controlled trials (RCTs) are needed.

Risks and Adverse Effects: Scientific Consensus

Of equal importance is the accumulating evidence with regard to the dangers of habitual or high-concentration cannabis use,
especially among susceptible groups:

• Neurodevelopmental risks: Longitudinal designs link early cannabis use with modifications in brain structure and functionality, especially in the prefrontal cortex and hippocampus regions, which are crucial in memory and executive functioning.
• Mental health implications: Evidence is coherent in the existence of a relation between heavy cannabis consumption and the increased risk of psychosis, particularly in cases of individuals with a genetic vulnerability or in those populations who consume high-THC strains. The links with depression and anxiety are less clear, may be bidirectional and are under further study.
• Dependence and withdrawal: Some studies have established the presence of Cannabis Use Disorder (CUD) which is composed of compulsive use, tolerance, and withdrawal symptoms which include irritability, sleep disorders, and craving.

Cannabis Constituents and the “Entourage Effect”

The direction of modern studies is also toward a more phytochemically comprehensive outlook by investigating the importance of minor cannabinoids (e.g., CBG, CBC, THCV) and terpenes in the regulation of the effects of cannabis. The theory of the entourage effect suggests that compounds in cannabis can have a synergistic effect in relation to their therapeutic effects,
producing a greater effect than the individual compounds, THC or CBD, alone. Although this theory is promising, it needs further and more rigorous testing using controlled studies.

The state-based medical marijuana systems usually entail that a patient should get a recommendation of a licensed healthcare practitioner and enroll in a state- operated database. Depending on the state, qualified medical conditions include:

• Chronic pain
• Cancer
• Epilepsy
• Multiple sclerosis
• HIV/AIDS
• PTSD

There are also regulations on the acceptable products (e.g., oils, capsules, edibles, flower), the limit of THC content, the licensing of dispensaries and the testing of products to guarantee safety to the consumer.

But, since it is not overseen by the feds there is wide variation in the quality of the products, the accuracy of labeling, and potency. The results of independent laboratory testing and standardization are not always comparable,
and this creates difficulties when a physician and the patient expect reproducible results of therapy.

Adult Use Legalization of Recreational Marijuana

Recreational or adult-use legalization means that people over the age of a particular threshold,
usually 21 years, can buy and use cannabis without a medical prescription. The regulations normally concern:

• Buy and possession restrictions
• Home growing permissibilities
• Sales tax and retail sales
• Laws on advertising
• Bans on public consumption

Recreational marijuana legalization states usually charge excise taxes, which bring £os of revenue that is commonly directed to education, healthcare, and public safety and drug. 

While legalization has benefits—such as reduced criminal justice costs and improved access for patients—there are concerns about over-commercialization, increased youth access, and health disparities if regulations are not carefully designed and enforced.

International Landscape

Globally, marijuana legalization varies widely. Canada, Uruguay, Malta, and Germany have legalized cannabis at the national level for adult use. Other countries maintain strict prohibition or allow limited medical use only. International treaties, such as the UN Single Convention on Narcotic Drugs (1961), continue to influence national drug policies, though some countries have begun challenging or reinterpreting these frameworks in light of evolving science and public opinion.

The use of marijuana could also impact on work performance especially in sectors where attention to details,
coordination or quick decision making is very essential like construction, transport, health care and policing sectors.

Acute and chronic effects of marijuana may include:

• Reduced levels of concentration and accuracy of the tasks
• Delayed response time
• Higher error rates and accident prone
• Fatigue and motivation loss, especially with long-term high-THC consumption

The problem is that employers have to find a balance between workplace safety and the rights of employees in the states where medical or recreational cannabis is legalized. The conventional drug screening procedures (e.g., urine tests) identify THC metabolites days after a person is no longer impaired, which only adds to the problem of managing risks and liability.

Accidental Ingestion and Pediatric Exposure

The recent spread of cannabis edibles,
with many taking the shape and form of candies or baked goods,
has caused a dramatic rise in accidental consumption, especially in children. In young children the ingestion of THC can lead to:

• Lethargy
• Respiratory depression
•  Loss of coordination
• In severe cases, seizures or coma

Unintentional pediatric exposure visits to the emergency department have increased dramatically in states where recreational cannabis is legal. As a possible solution, a number of states currently implement child-resistant packaging, dose limits of THC, and edible cannabis products labeling. 

Fire Hazards and Environmental Concerns

In home-grow operations or unregulated production settings,
marijuana cultivation and extraction can introduce additional safety risks:

• Electrical fires due to improper wiring or lighting setups
• Explosions caused by the use of flammable solvents in hash oil extraction
• Mold growth and indoor air quality hazards from poor ventilation

Ensuring compliance with local building codes and occupational safety regulations is essential for minimizing hazards in both home and commercial grow settings.

Legalization and Regulation

Over the past few decades, the legal status of marijuana has experienced a dramatic change ranging between total prohibition to a quilt of medical, decriminalized, and outright legalized systems in most jurisdictions. Even though this development indicates increased acceptability and recognition by the populace of the therapeutic potential of marijuana, there are regulatory, legal, and population health issues arising.

Federal State Differences

In the United States, marijuana is a Schedule I controlled substance by the Controlled Substances Act (CSA), which is the same legal status as heroin and LSD. The federal law states that Schedule I drugs are those which have no accepted medical use and a high potential to be abused, a designation that many scientists claim is no longer valid in light of modern science.

On the other hand, by 2025, marijuana will be legalized in 38 states of the United States and various territories with the country allowing its use in medicine, while 24 states and the District of Columbia have already legalized its recreational use by adults. Such state policies are constantly in contrast with federal law, which puts both consumers, healthcare providers, researchers, and businesses active in the cannabis sector in a legally uncertain position.

Such as, a state may legalize marijuana dispensaries,
but the dispensaries can also be subject to federal banking regulations,
IRC code constraints, and cannot receive federal grants or protection. And similarly, health providers working in federal systems (e.g., VA hospitals) might not be able to advise or even counsel on cannabis treatments, even in states where it is legal.

With the rising popularity of medical marijuana, more and more older adults are turning to cannabis as a part of their wellness practices in order to treat illnesses like chronic pain, arthritis, sleep disorders, and neurodegenerative diseases.

However, this population also faces elevated risks, including:

• Drug interactions with commonly prescribed medications (e.g., anticoagulants, sedatives)
• Increased fall risk due to cannabis-induced dizziness or hypotension
• Delayed metabolism and excretion, which may enhance drug potency and prolong effects

Additionally, the lack of standardized dosing guidelines and variability in product potency further complicate cannabis use in geriatric populations.

Clinicians are encouraged to take detailed histories regarding cannabis use, especially among patients managing multiple chronic conditions. Education on titration, non-inhaled routes of administration, and THC/CBD ratios is essential to optimizing safety.

Marijuana and Safety

Due to the growing accessibility of marijuana with the medical and recreational legalization, the safety consequences of marijuana, particularly in the public, work-related, and home circumstances have been given more consideration. Motor coordination, judgment, and reaction time are some of the important functions that can be impaired by the psychoactive properties of THC and this is why the use of marijuana is an increasing threat to public safety, especially when it comes to driving, job performance, and accidental exposure.

Drunk driving and Road safety

Drug-impaired driving is one of the most urgent safety issues that can be related to the use of marijuana. THC has a detrimental impact on the motor and cognitive abilities needed to operate a vehicle safely and these include:

• Shorter response time
• Poor short term memory and attention
• Altered sense of space
• Impaired power of decision making

Driving under the influence of marijuana has been shown to increase the risk of motor vehicle collision especially when drivers indulge in the drug 1-3 hours before driving. In contrast to alcohol, the impairment of THC does not correlate linearly with the concentration in the blood, which makes it difficult to formulate per se legal limits.

Also, poly-drug use, particularly, marijuana and alcohol, is synergistic, and it dramatically increases impairment and the risk of accidents. With increasing jurisdictions across the globe legalizing cannabis, drug recognition training of the law enforcement and community education are the crucial elements in the responses to marijuana-impaired driving incidences.

Not everyone will have an equal experience on the health effects of marijuana. Some groups of people, such as adolescents, pregnant and breastfeeding women, and elderly persons, are particularly susceptible to physiological, neurological, and behavioral impacts of cannabis. In such populations, even moderate use may lead to an increase in risks or peculiar complications, which should be the subject of special public health recommendations and clinical precautions.

The Teen and Brain Development

The neurodevelopmental perspective adolescence is a crucially important time in human development when the brain is continuing to grow and develop, especially in areas related to executive functioning, impulse control, decision-making, and emotion regulation. Over the years, numerous longitudinal studies have revealed that early-onset marijuana use (usually considered use before age 18) has the potential to interfere with these developmental processes.

Exposure to THC at adolescence has been linked with:

• Slower thinking and poorer memory, attention, and learning performances.
• Anatomical alteration in brain regions like prefrontal cortex and the hippocampus.
• Greater risk of psychiatric illness, such as anxiety, depression and schizophrenia, especially among those with a genetic vulnerability.
• Increased risk of cannabis use disorder (CUD) during adulthood.

The given results highlight the necessity of evidence-based prevention work with young people, and policies that limit the access of underage groups to high-potency cannabis products.

Pregnancy, Breast feeding and Pediatric Exposure

The use of cannabis during pregnancy poses significant hazards to the mother and the unborn child. THC does penetrate the placental barrier and impact fetal development, endocannabinoid system included the latter is involved in neural differentiation and brain development.

Studies have associated prenatal marijuana with:

• Low Birth weight
• Dulled thinking
• Childhood and adolescent behavior problems

Despite the fact that some pregnant people might take marijuana to relieve nausea or nervousness, at present, no FDA-approved cannabis products are available to treat symptoms related to pregnancy. American College of Obstetricians and Gynecologists (ACOG) highly discourages the use of marijuana during pregnancy and lactation.

THC has also been known to be excreted in breast milk in the postpartum period,
which induces concerns about accidental exposure in infancy,
which is a period of fast neurodevelopment. Although there is limited information on the long-term effects among exposed infants,
precautionary principles would dictate that avoidance is the most prudent thing to do.

The symptoms of using marijuana are complex and still remain the focus of considerable clinical and epidemiological study. Although there is growing evidence of the therapeutic potential of some compounds found in cannabis, these effects should be balanced against the well-described harms – especially when use is chronic, high-dose, or starts early in life. It is crucial to be knowledgeable about both sides because marijuana is getting more accessible in the United States.

Therapeutic Applications

Cannabis and its derivatives proved to be effective in a number of medical disorders, but clinical effects differ depending on a formulation, dosage, and a route of administration. The most supported medicinal applications consist of:

• Chronic pain Medical cannabis, particularly products with a high-THC concentration or equal THC:CBD ratio, has demonstrated the ability to lessen neuropathic and musculoskeletal pain in select patients. Although it is not universally effective, it can provide an alternative to opioid in some instances.
• Epilepsy: CBD, namely in the recently approved FDA Epidiolex, has shown itself capable of reducing the number of seizures in rare epilepsy syndromes, including Dravet syndrome and Lennox-Gastaut syndrome.
• Multiple sclerosis (MS): Some cannabis extracts proved to decrease spasticity and enhance sleep quality in people with MS.
• Chemotherapy-induced nausea and vomiting (CINV): THC-based medicines (e.g., dronabinol) have been useful in managing chemotherapy-induced nausea that is resistant in cancer patients.

There is also an emerging body of evidence that implicates many uses of cannabinoids in the treatment of anxiety,
PTSD, inflammatory diseases, and neurodegenerative disorders. Nevertheless, well-built,
extended randomized controlled trials are yet to be carried out to provide a clearer understanding of efficacy, dose-response relationships, and safety.

Short-Term Effects

The acute usage of marijuana has dose-dependent effects, which may differ markedly among individuals. The short term effects are:

• Euphoria or relaxation, usually with changed perception of time and sociability.

 

• Mental failures, such as shortened attention span, damaged memory and decreased reaction time.
• Anxiety, panic attacks or paranoia, particularly among first time users or with use of high potency THC products.

A psychomotor damage is also a significant issue,
especially when it comes to driving or using machinery,
because even THC may decrease coordination and reaction time several hours after consumption.

Long Term Health Risks

Heavy and prolonged use of marijuana,
particularly when it is started at an early age, has been linked to various negative health effects:

• Respiratory: Smoked marijuana has been used frequently via inhalation, thus causing symptoms of chronic bronchitis and inflammation of the airways. Although marijuana does not have all the carcinogens that are present in tobacco, the smoke does contain harmful particulates and the habit of deep inhalation could worsen the irritation to the lungs.
• Mental health: There has been an association with long-term use and increased risk of anxiety disorders, depression, and psychosis, especially in people with a genetic predisposition or those who start using it early. Some evidence also shows that excessive use of cannabis can reduce motivation or cognitive functioning with time.
• Addiction potential: Despite the common assumption, marijuana is habit forming. According to the estimations of the National Institute on Drug Abuse (NIDA), around 9 percent of users will develop cannabis use disorder (CUD), and the rate rises to 17 percent when individuals start using it during adolescence.

The risks and potential medical benefits of marijuana have to be weighed using a sophisticated,
evidence-based approach. Although cannabis might be an effective instrument in some therapeutic settings,
its misuse and excessive use have real health implications, which are worth considering not only of clinicians or policymakers but also of the general population.

To appreciate the interactions of marijuana with the human body,
it is important to first understand the endocannabinoid system (ECS)- a complicated cellular signaling system involved in physiological homeostasis. It is through the interactions of the main components in marijuana; mainly THC and CBD with this system and associated molecular pathways that the pharmacological effects of this drug are achieved.

The Essentials of the Endocannabinoid System -CB1 & CB2 Receptors

There are three main components of the endocannabinoid system (ECS):

1. Endogenous lipid-based neurotransmitters (endocannabinoids) anandamide and 2-AG
2. Cannabinoid receptors (mainly CB1 and CB2)
3. Synthetic and degradative enzymes of endocannabinoids (i.e. FAAH and MAGL)

CB1 receptors are mostly located in the central nervous system- particularly in brain areas that deal with cognition, memory, motor coordination and mood. The psychoactive properties of THC are mainly caused by binding of cannabinoids to CB1 receptors. In contrast, CB2 receptors are mainly found in peripheral tissues, especially inside immune cells, and they regulate inflammation and immune responses considerably.

 

When foreign cannabinoids like THC or CBD are implemented into the body through the use of marijuana, they react with these receptors, imitating or alloying the natural endocannabinoids of the body. The result of this interaction is a cascade of physiologic effects which differ according to the compound, dose, method of delivery, and biological differences of the individual.

THC vs. CBD: Head High vs. Medicate

Delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids that exhibit completely different mechanisms and effects.

THC is a partial CB1 agonist, which implies that it connects directly and stimulates CB1 receptors, especially in the brain. This is the main action that causes the happy and intoxicated feelings of marijuana. THC also affects memory, attention, appetite and perception and in large amounts it can provoke anxiety or psychotic-like symptoms in some people.

CBD on its part does not have high affinity to bind to either CB1 or CB2 receptors. Rather, it acts as an indirect ECS modulator. It also increases anandamide (a naturally occurring endocannabinoid) by inhibiting the FAAH enzyme, and acts at other receptor systems including 5-HT1A (serotonin), TRPV1 (pain) and GPR55 (inflammatory regulatory). These attributes add to the non-intoxicating, prospective therapeutic properties of CBD, such as anxiolytic, anti-seizure, anti-inflammatory, and neuroprotective effects.

 

Pharmacokinetics: absorption, metabolism, excretion

The pharmacokinetics of marijuana, its absorption, metabolism and elimination, differ according to the route of administration:

• Inhalation (smoking or vaping): Fast acting (minutes), peak plasma THC concentration at 10-15 minutes. Bioavailability is 10 35%.
• Oral ingestion (edibles, capsules): Longer onset (30 90 minutes), Peaks in 2 3 hours. In the liver, first-pass metabolism, 11-hydroxy-THC is a more psychoactive metabolite of THC. Bioavailability is generally less (~412%).
• Topical/Transdermal: This is mostly applicable in cases of local actions, where absorption is minimal.

THC and its metabolites are lipophilic, and thus distribute in fatty tissues, resulting in long elimination half-lives, up to several days in occasional users and weeks in regular users. CBD has a similar profile though it tends to be metabolized faster and does not accumulate to the same level.

Knowledge of these mechanisms is essential to interpret the wanted effects as well as the risks of using marijuana, especially in clinical, legal, and safety-related aspects.

 Marijuana is the psychoactive substance which is a product of the Cannabis plant mainly the Cannabis sativa,
Cannabis indica and the hybrid strains. The pharmacological and therapeutic effect of the plant is explained by the complex composition of cannabinoids,
terpenes, and other phytochemicals. Although marijuana is commonly used as a colloquialism,
in scientific circles the plant is generally referred to by its genus (Cannabis) or,
to be precise and unambiguous, one can specify which of its bioactive components are of interest.

Taxonomy of Cannabis: Sativa, Indica and Hybrids

Cannabis genus is broadly classified into three broad forms which include: Cannabis sativa, Cannabis indica and Cannabis ruderalis. Among these,
sativa and indica are the most common ones which are grown both as recreational and medicinal purposes.

• Cannabis sativa boasts a taller plant morphology,
  has longer flowering time and its chemical composition tends to relate to stimulating effects.
• Cannabis indica, on the contrary, is more bushy and shorter,
  and its chemical composition is associated with sedative effects.

Hybrid strains GM Varying degrees of the genetic material of both sativa and indica plants are combined to produce custom cannabinoid and terpene profiles that are meant to produce a desired effect.

One should mention that researchers are more and more doubtful about these traditional classifications because of the lack of consistency in strain designations and Variability in chemical content, even among strains of the same designation.

Main Cannabinoids: THC, CBD, and More

Cannabinoids, a group of more than 100 structurally related compounds, are the most famous active components in marijuana, and they bond with cannabinoid receptors in the human body. The two most important and analyzed cannabinoids are:

• Delta-9-tetrahydrocannabinol (THC): It is the main intoxicating chemical that produces the high, which is implemented when marijuana is used. The main effects of THC are related to its binding to CB1 receptors in brain and central nervous system, which affect mood, memory, motor control and perception.
• Cannabidiol (CBD): Non-intoxicating cannabinoid that has received growing scientific and clinical interest in recent years, as it may have potential therapeutic uses, such as anti-inflammatory, anxiolytic, or anti-epileptic. In contrast with THC, CBD does not bind well to CB1 receptors and does not generate euphoria or impairment.

Minor cannabinoids, including cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabivarin (THCV) among others, also occur and are being studied due to their various pharmacological actions.

Terpenes, flavonoids and the entourage effect

In addition to cannabinoids, Cannabis plants synthesize terpenes, aromatic organic compounds that possibly add to the physiological effects of the plant as well as its odor. Myrcene, limonene, linalool, and beta-caryophyllene are examples, and each of them can adjust the mood, inflammation, or sedation. Marijuana also contains flavonoid, a type of polyphenolic compound and may possess anti-inflammatory and antioxidant properties.

The entourage effect is a hypothesis suggesting that cannabinoids, terpenes, and flavonoids work synergistically to enhance therapeutic outcomes, rather than acting in isolation. This concept underscores the importance of whole-plant preparations in some medical marijuana formulations, although more clinical evidence is needed to validate these synergistic interactions.

One of the most complicated and controversial substances in contemporary pharmacology,
public health and criminal justice is marijuana, a common term used to refer to the dried leaves, flowers,
stems and seeds of the Cannabis sativa or Cannabis indica plant.

Marijuana contains hundreds of biologically active compounds,
the most significant of which is delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD),
thus having a wide scope of physiological, psychological, and behavioral effects.
Although people have been using it throughout centuries as a medicine and recreational drug,
today marijuana exists at the confluence of science, policymaking, and popular imagination.

Within this atmosphere of swift legalization crusades and evolving popular opinion the need to have ready, science-based facts about marijuana has never been more pressing.

This technical summary is aimed at providing the adult reader (healthcare professional,
policy maker, educator and concerned citizen) with an evidence-based, technically accurate perspective on the biological actions,
clinical impacts and social consequences of marijuana.

National Marijuana Initiative (NMI), which is among the national initiatives of the High Intensity Drug Trafficking Areas (HIDTA) program, is dedicated to ensuring the objective and balanced marijuana education.

A proven leader in drug policy, public safety, and data-driven education with decades of experience, the NMI provides partners at the local, state, and federal level with the resources necessary to educate stakeholders on the public health and safety impacts of marijuana use, particularly when use is frequent, early-onset, or when use is in high-potency forms.

This paper will discuss marijuana in a multidisciplinary approach starting with the biology and chemical constituent of the plant, then its action on the endocannabinoid system.

It will discuss its use as a therapy, negative health impacts, potential to cause addiction, as well as effects on special populations including adolescents and pregnant people.
The aspects of marijuana use in traffic safety, workplace performance,
and the health infrastructure of the population will be discussed as well.

Such environmental and regulatory issues as the ones linked to illicit cultivation and trafficking will also be considered with respect to the mission of the NMI to minimize harm related to drugs and to support evidence-based practices.

The article ends with a harm reduction advice, community education gems, and future research directions in the ever-changing marijuana environment.

In an era of quickly changing marijuana regulations,
market forces, and consumer patterns, technical fluency about this subject matter is a prerequisite.

Regardless of whether one uses marijuana therapeutically,
recreationally, or as an experiment,
being aware of the full range of its effects allows making decisions at the personal and policy levels.

This resource will provide such understanding.

This guide demonstrates the commitment of the NMI to community safety and responsible drug education through precise language and peer-reviewed information as well as the input of professionals in the field.